Genetically altered antibody-producing cell lines with improved antibody characteristics
원문보기
IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
UP-0933034
(2004-09-02)
|
등록번호 |
US-7604994
(2009-11-10)
|
발명자
/ 주소 |
- Grasso, Luigi
- Nicolaides, Nicholas C.
- Sass, Philip M.
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 |
피인용 횟수 :
1 인용 특허 :
4 |
초록
▼
Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. Cells may be selected for expression of activation-induced cytidine deaminase (AID), stimulated to produce AID, or manipulated to express AID for further enhancement of hypermutability.
Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. Cells may be selected for expression of activation-induced cytidine deaminase (AID), stimulated to produce AID, or manipulated to express AID for further enhancement of hypermutability. These methods are useful for generating genetic diversity within immunoglobulin genes directed against an antigen of interest to produce altered antibodies with enhanced biochemical activity. Moreover, these methods are useful for generating antibody-producing cells with increased level of antibody production.
대표청구항
▼
What is claimed is: 1. A method for generating a hypermutable antibody-producing cell in vitro comprising introducing into an antibody-producing cell a polynucleotide comprising a nucleic acid sequence encoding a PMS2 having an ATPase domain, wherein expression of said polynucleotide inhibits misma
What is claimed is: 1. A method for generating a hypermutable antibody-producing cell in vitro comprising introducing into an antibody-producing cell a polynucleotide comprising a nucleic acid sequence encoding a PMS2 having an ATPase domain, wherein expression of said polynucleotide inhibits mismatch repair, wherein inhibition of mismatch repair stimulates expression of activation-induced cytidine deaminase, thereby generating a hypermutable antibody-producing cell. 2. The method of claim 1 wherein said PMS2 is a mammalian PMS2. 3. The method of claim 1 wherein said PMS2 is a rodent PMS2. 4. The method of claim 1 wherein said PMS2 is a human PMS2. 5. The method of claim 1 wherein said PMS2 is a plant PMS2. 6. The method of claim 1 further comprising the step of inactivating the polynucleotide, thereby producing a genetically stable antibody-producing cell. 7. A method for producing hybridoma cells producing antibodies from in vitro immunized immunoglobulin-producing cells comprising: (a) combining cells capable of producing immunoglobulins with an immunogenic antigen in vitro; (b) fusing said cells with myeloma cells to form parental hybridoma cells, wherein a polynucleotide comprising a nucleic acid sequence encoding a PMS2 having an ATPase domain is transfected into said hybridoma cells, wherein expression of said polynucleotide inhibits mismatch repair; (c) selecting for mismatch repair-inhibited hybridoma cells exhibiting increased expression of activation-induced cytidine deaminase relative to mismatch repair-proficient parental hybridoma cells, wherein expression of activation-induced cytidine deaminase is stimulated by said inhibition of mismatch repair; (d) incubating the selected mismatch repair-inhibited hybridoma cells to allow for mutagenesis, thereby forming hypermutated hybridoma cells; and (e) selecting hypermutated hybridoma cells that produce antibodies that specifically bind antigen, thereby producing hybridoma cells producing antibodies from in vitro immunized immunoglobulin-producing cells. 8. The method of claim 7 wherein said activation-induced cytidine deaminase is a mammalian activation-induced cytidine deaminase. 9. The method of claim 8 wherein said activation-induced cytidine deaminase is a human activation-induced cytidine deaminase. 10. The method of claim 7 wherein said activation-induced cytidine deaminase is a mouse activation-induced cytidine deaminase. 11. The method of claim 7 wherein said polynucleotide encodes a truncated form of a PMS2 protein. 12. The method of claim 11 wherein said PMS2 is a plant PMS2. 13. The method of claim 11 wherein said PMS2 is a mammalian PMS2. 14. The method of claim 13 wherein said PMS2 is a human PMS2. 15. A method for producing hybridoma cells producing antibodies from in vitro immunized immunoglobulin-producing cells comprising: (a) combining cells capable of producing immunoglobulins with an immunogenic antigen in vitro; (b) fusing said cells with myeloma cells to form parental hybridoma cells, wherein a polynucleotide comprising a nucleic acid sequence encoding a PMS2 having an ATPase domain is transfected into said myeloma cells, wherein expression of said polynucleotide inhibits mismatch repair; (c) selecting for mismatch repair-inhibited hybridoma cells exhibiting increased expression of activation-induced cytidine deaminase relative to mismatch repair-proficient cells, wherein expression of activation-induced cytidine deaminase is stimulated by said inhibition of mismatch repair; (d) incubating the selected mismatch repair-inhibited hybridoma cells to allow for mutagenesis, thereby forming hypermutated hybridoma cells; and (e) selecting hypermutated hybridoma cells that produce antibodies that specifically bind antigen, thereby producing hybridoma cells producing antibodies from in vitro immunized immunoglobulin-producing cells. 16. A method for producing hybridoma cells producing antibodies from in vitro immunized immunoglobulin-producing cells comprising: (a) combining cells capable of producing immunoglobulins with an immunogenic antigen in vitro, wherein a polynucleotide comprising a nucleic acid sequence encoding a PMS2 having an ATPase domain is transfected into said cells capable of producing immunoglobulins, wherein expression of said polynucleotide inhibits mismatch repair; (b) fusing said cells with myeloma cells to form parental hybridoma cells; (c) selecting for mismatch repair-inhibited hybridoma cells exhibiting increased expression of activation-induced cytidine deaminase relative to mismatch repair-proficient cells, wherein expression of activation-induced cytidine deaminase is stimulated by said inhibition of mismatch repair; (d) incubating the selected mismatch repair-inhibited hybridoma cells to allow for mutagenesis, thereby forming hypermutated hybridoma cells; and (e) selecting hypermutated hybridoma cells that produce antibodies that specifically bind antigen, thereby producing hybridoma cells producing antibodies from in vitro immunized immunoglobulin-producing cells. 17. A method for generating a hypermutable antibody-producing cell in vitro comprising: introducing into an antibody-producing cell a polynucleotide comprising a nucleic acid sequence encoding a PMS2 having an ATPase domain, wherein expression of said polynucleotide inhibits mismatch repair, thereby generating a mismatch repair-inhibited antibody-producing cell; culturing said mismatch repair-inhibited antibody-producing cell to yield a population of mismatch repair-inhibited antibody-producing cells; and selecting a mismatch repair-inhibited antibody-producing cell from said population that exhibits increased expression of activation-induced cytidine deaminase relative to mismatch repair-proficient antibody-producing cells, wherein inhibition of mismatch repair in said mismatch repair-inhibited antibody-producing cell by said expression of said polynucleotide increases expression of activation-induced cytidine deaminase relative to mismatch repair-proficient antibody-producing cells; thereby generating a hypermutable antibody-producing cell. 18. The method of claim 17 wherein said antibody-producing cell is a hybridoma cell. 19. The method of claim 17 wherein said antibody-producing cell is a mammalian expression cell transfected with polynucleotides encoding immunoglobulin heavy and light chains. 20. The method of claim 1 wherein said PMS2 is PMS2-134. 21. The method of claim 20 wherein said PMS2-134 is encoded by the nucleic acid sequence SEQ ID NO:5, SEQ ID NO:33, or SEQ ID NO:37. 22. The method of claim 7 wherein said PMS2 is PMS2-134. 23. The method of claim 22 wherein said PMS2-134 is encoded by the nucleic acid sequence SEQ ID NO:5, SEQ ID NO:33, or SEQ ID NO:37. 24. The method of claim 15 wherein said PMS2 is PMS2-134. 25. The method of claim 24 wherein said PMS2-134 is encoded by the nucleic acid sequence SEQ ID NO:5, SEQ ID NO:33, or SEQ ID NO:37. 26. The method of claim 16 wherein said PMS2 is PMS2-134. 27. The method of claim 26 wherein said PMS2-134 is encoded by the nucleic acid sequence SEQ ID NO:5, SEQ ID NO:33, or SEQ ID NO:37. 28. The method of claim 17 wherein said PMS2 is PMS2-134. 29. The method of claim 28 wherein said PMS2-134 is encoded by the nucleic acid sequence SEQ ID NO:5, SEQ ID NO:33, or SEQ ID NO:37.
이 특허에 인용된 특허 (4)
-
Queen Cary L. (Los Altos CA) Selick Harold E. (Belmont CA), Humanized immunoglobulins.
-
David Gary S. (La Jolla CA) Greene Howard E. (Carlsbad CA), Immunometric assays using monoclonal antibodies.
-
Nicolaides, Nicholas C.; Grasso, Luigi; Sass, Philip M., Methods for generating genetically altered antibody producing cell lines with improved antibody characteristics.
-
Winkelhake Jeffrey L. (Emeryville CA), Myelomas for producing human/human hybridomas.
이 특허를 인용한 특허 (1)
-
Grasso, Luigi; Nicolaides, Nicholas C.; Sands, Howard; Sass, Philip M., Antibodies and methods for generating genetically altered antibodies with enhanced effector function.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.